Last updated October 2, 2024
The obesity market will become the largest – and most competitive – in pharma history.
This chart helps you see which drugs are likely to be best-in-class as the market evolves.
The chart shows the latest clinical data for select obesity drugs, so you can see how competing drugs stack up.
Select a year from the dropdown below to see the drugs that are expected to be on the market in that year.
You can also click a line in the chart to see more detail on the clinical data for a given drug.
Year of approval is estimated for drugs currently in clinical development. Estimates may be incorrect. Year of approval is for obesity / overweight indication, not Type 2 Diabetes or other indications.
The chart only includes drugs with published clinical data. There are many more drugs in development than displayed on this chart. Some of the listed drugs may not ultimately be approved.
This chart shows the placebo-adjusted weight loss over time for select novel anti-obesity medications. Each line represents a clinical study.
Data shown in the chart represents efficacy estimand where available. Efficacy estimands generally represent the analysis of the patients who remained on the drug throughout duration of the study (ie, with no dropouts, loss-to-follow-up, etc). Treatment-regimen estimands generally include all trial participants regardless of adherence to therapy. Most charts of weight loss over time show efficacy estimands, while treatment-regimen estimands can be important or primary endpoints. In some cases, the primary endpoint is a treatment-regimen estimand, in which cases reported weight loss numbers will differ from those shown in the chart.
Each line represents a different study. Differences in study design make it so no two studies are directly comparable. The chart only shows outcomes from studies of obese or overweight patients, and excludes studies of these agents in Type 2 Diabetes or other indications except where explicitly noted. Not all obesity studies are included in the chart.
In CagriSema studies, the comparator was placebo + semaglutide. To make the results of this study comparable to placebo-adjusted weight loss from other studies, we have added the placebo-adjusted weight loss for semaglutide trials to the placebo+semaglutide adjusted weight loss seen with CagriSema.
MET-097 did not report placebo weight loss for its Phase 1 study. We have assumed 1% weight loss by day 36 for the placebo arm.
To hide or show studies, click on a study in the chart's legend.
* Only includes studies with available weight loss data in obese / overweight patients; does not include studies in Type 2 Diabetes or other indications